Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAGISA trial of neoadjuvant S-1 plus oxaliplatin for locally advanced gastric cancer
jRCTs031180350Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur, oxaliplatin and docetaxel in gastric cancer (GC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Sep 2016; status: active, not recruiting.
02
Drugs
tegafuroxaliplatindocetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs031180350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180350.